- Home
- Products
- Customized FluoroAb™
- ERBB3
- Anti-ERBB3 MAb (Clone 13)-iFluor® 350 Succinimidyl Ester
Anti-ERBB3 MAb (Clone 13)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1261)
This product is comprised of an Anti-ERBB3 scFv-ALB (Clone 13) labeled with iFluor® 350 Succinimidyl Ester. iFluor® 350 Succinimidyl Ester is a Blue-fluorescent dye and it's excitation/emission is 345/450 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB3
- Alternative Names
- ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2; lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3; tyrosine kinase-type cell surface receptor HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; MGC88033;
- Overview
- This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
- Overview
- Anti-ERBB3 scFv-ALB (Clone 13)
- Species Reactivity
- Human
- Name
- iFluor® 350 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 345/450
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS1261. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-2243 | Anti-ERBB3 (Duligotumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2245 | Anti-ERBB3 (Duligotumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2244 | Anti-ERBB3 (Duligotumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2367 | Anti-ERBB3 (Duligotuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2370 | Anti-ERBB3 (Duligotuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CTLA4 MAb (Clone 14)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1246)
- Anti-MUC16 MAb (Clone 6)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11234)
- Anti-MET MAb (Clone 13)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2944)
- Anti-CTAA16.88 MAb (Clone 2)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10808)
- Anti-PCSK9 MAb (Clone 8)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS7596)
- Anti-GUCY2C MAb (Clone 2)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14272)
- Anti-IL1B MAb (Clone 2)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6777)
- Anti-FZD1 MAb (Clone 2)-iFluor® 555 Succinimidyl Ester (CAT#: WJY0-LS16644)
- Visilizumab-iFluor 594 (CAT#: ADC-FL-584)
- Anti-191P4D12 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14108)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
